Medical sector’s EyePoint Pharmaceuticals’s (NASDAQ:EYPT) Buy rating Reiterated by HC Wainwright

EyePoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its Buy rating Reiterated by analysts at HC Wainwright in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 311.6M and a beta of 1.25.  EyePoint Pharmaceuticals has a twelve month low $3.51 of  and a twelve month high of $15.06.

Shares of EyePoint Pharmaceuticals traded up $0.65 on Tuesday, reaching $10.83. 587,208 shares of the stock traded hands, compared to its average volume of 109537. Shares of EyePoint Pharmaceuticals at close on Tuesday were at $10.83. The firm’s 50 day moving average is $10.31 and its 200 day moving average is 10.05.EyePoint Pharmaceuticals  has a 12 month low of $10.12 and a 12 month high of $15.06. While on yearly highs and lows, EyePoint Pharmaceuticals’s today has traded high as $11.05 and has touched $10.12 on the downward trend. See More Analyst Rating at: RATING

EyePoint Pharmaceuticals (NASDAQ:EYPT) Moving Average Technical Analysis

5 day Moving Average is 10.38 And 5 day price change is 0.14 (1.31%)  with average volume for 5 day average is 85,980. While technical analysis for average 20 days shows significant difference, 20 day moving average is  10.67 and 20 day price change is 0.89 (8.95%) and average 20 day moving volume is 119,270. 50 day moving average is 10.31  and 50 day price change is 2.51 ( 30.17%)  and with average volume for 50 days is : 117,252. 200 day moving average is 10.05  and 200 day price change is 5.84 (1.1703)  and with average volume for 200 days is : 235,749.

See More Analyst Rating at: RATING

EyePoint Pharmaceuticals Earnings and What to expect: 

EyePoint Pharmaceuticals last announced its quarterly earnings data on August 4th, 2021. The reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.10. The firm earned $9.01 million during the quarter, compared to analysts’ expectations of $8.80 million. EyePoint Pharmaceuticals has generated ($3.47) earnings per share over the last year (($2.22) diluted earnings per share). Earnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($1.69) to ($1.86) per share. EyePoint Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for EyePoint Pharmaceuticals are expected to decrease in the coming year, from ($1.69) to ($1.86) per share. The P/E ratio of EyePoint Pharmaceuticals is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of EyePoint Pharmaceuticals is -4.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. EyePoint Pharmaceuticals has a P/B Ratio of 10.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Other owners latest trading in EyePoint Pharmaceuticals :

  • On 8/25/2021 shares held by Marshall Wace LLP were 37,746 which equates to market value of $0.34M and appx 0.00% owners of EyePoint Pharmaceuticals
  • On 8/25/2021 shares held by Marshall Wace North America L.P. were 55,325 which equates to market value of $0.50M and appx 0.00% owners of EyePoint Pharmaceuticals
  • On 8/23/2021 shares held by Morgan Stanley were 16,744 which equates to market value of $0.15M and appx 0.00% owners of EyePoint Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 72.12% for EyePoint Pharmaceuticals

See More Analyst Rating at: RATING